| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_25202fe4a5c7293a0a5e07026316bf12 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4468 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 |
| filingDate |
2021-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3bc2abf4db9537cf506e1cd4478c0a8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a357c20b4e5c4806f9bef9804042389
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4670a8e08064244704f7ffc41e86066d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73f0ca64821619fd9797c7fe69da6318
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3bd2cdcac4b6eeb4e64a3ed1bcee7b6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8a5a6ec71141370a3d6a38290f88c7b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d0d7a0d6593fb7eb665ec9ee8816f65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbcd7f0ec850e5942ad91bdce2633ec1 |
| publicationDate |
2021-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-113797200-A |
| titleOfInvention |
Application of small molecule compound pimavanserin in the preparation of anti-SARS-CoV-2 drugs |
| abstract |
The invention discloses the application of the small molecular compound pimavanserin in the preparation of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) medicine, the anti-SARS-CoV-2 medicine is pimavanserin Lin is the only active ingredient, or a pharmaceutical composition comprising pimavanserin, and the anti-SARS-CoV-2 drug refers to a drug for preventing or treating SARS-CoV-2 infection. The invention utilizes SARS-CoV-2 susceptible cell lines, including African green monkey kidney cell Vero E6 and human lung adenocarcinoma cell Calu-3, to detect the anti-SARS-CoV-2 activity of pimavanserin. The experimental results show that pimavanserin can effectively inhibit the infection of the above-mentioned susceptible cells by SARS‑CoV‑2 with less cytotoxicity. It is promising as an effective drug against SARS‑CoV‑2 infection and has application prospects. |
| priorityDate |
2021-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |